
    
      The device is currently under investigation with IDE #G110030. This continued access study
      will enroll subjects that have participated in the Smart-AF IDE study. Subjects with drug
      refractory symptomatic paroxysmal atrial fibrillation (PAF) will be considered for this
      study. Effectiveness and safety endpoints have been defined and will be evaluated post
      treatment.
    
  